# Are psychedelics good for us? | Norman Ohler vs Joanna Moncrieff

Source: https://www.youtube.com/watch?v=S6Smi0GisB0
Recap page: https://rapidrecap.app/video/S6Smi0GisB0
Generated: 2025-09-30T14:34:38.507+00:00

---
## Quick Overview

Norman Ohler argues that psychedelics like LSD are fundamentally different from addictive drugs like cocaine and should not be treated identically, citing historical use and neurological evidence, while Joanna Moncrieff counters that the current medical trend of promoting psychedelics as a replacement for conventional antidepressants is worrying because the clinical trial evidence for long-term benefits is lacking, and the focus on their supposed spiritual benefits distracts from the need for better, safer treatments.

**Key Points:**
- Norman Ohler asserts that psychedelics such as LSD are non-addictive and promote neuroplasticity, contrasting them with cocaine, which he describes as an addictive 'talking drug' associated with detrimental historical use.
- Ohler points to archaeological evidence, like cup residue from ancient Egypt, suggesting long-term ritualistic use of psychoactive compounds by humans, unlike Neanderthals.
- Joanna Moncrieff expresses concern that psychedelics are being promoted as a replacement for antidepressants (like SSRIs or benzodiazepines) without sufficient long-term evidence of benefit, calling the current approach potentially dangerous.
- Moncrieff notes that while some people experience positive insights from psychedelic-assisted therapy, society's normalization of their use overlooks the lack of robust, long-term clinical trial data.
- She highlights that the current clinical evidence does not definitively show psychedelics are superior for treating conditions like PTSD or alcoholism compared to existing methods, and their high cost makes them inaccessible for widespread, regular use.
- The discussion centers on the ethical and practical implications of rapidly integrating psychedelics into mainstream medical practice, contrasting the historical context of ritual use with modern therapeutic application.

![Screenshot at 0:01: Norman Ohler passionately gesturing while arguing about the fundamental differences between psychedelics and addictive substances during the panel discussion.](https://ss.rapidrecap.app/screens/S6Smi0GisB0/00-00-01.png)

**Context:** This video features a debate or discussion titled "Out of Our Minds," involving Norman Ohler, author of *Blitzed: Drugs in the Third Reich*, and Joanna Moncrieff, a psychiatrist and academic. The central theme revolves around the current surge in interest regarding the therapeutic potential of psychedelics (like LSD and psilocybin) and whether they should be integrated into medical practice, contrasting their effects and historical context with traditional addictive substances.

## Detailed Analysis

The discussion immediately dives into the nature of psychedelics versus addictive drugs. Norman Ohler strongly contends that substances like LSD are not inherently addictive, contrasting them with drugs like cocaine, which he characterizes as addictive and historically linked to destructive behavior, particularly in the context of the Third Reich. He argues that if LSD does not deplete the control center of the brain of energy like chronic use of addictive drugs does, it should be treated differently. Ohler also references archaeological evidence suggesting ancient cultures used psychoactive brews ritually for millennia, implying a different relationship with these substances than the one we have with modern addictive drugs. Joanna Moncrieff, however, raises a critical counterpoint regarding the current medical push. She worries that psychedelics are being promoted as a cure-all, poised to replace established medications like SSRIs for conditions like depression and PTSD, despite lacking sufficient long-term clinical evidence demonstrating superior efficacy or safety. Moncrieff notes that while some individuals gain insights from these experiences, the current hype surrounding them, often fueled by pharmaceutical interests, may be leading society to embrace them too quickly, especially given the high expense of assisted psychotherapy sessions, which limits accessibility. The panel collectively questions the societal rush to adopt these compounds medicinally without fully understanding the long-term cognitive or neuroplastic implications, fearing a simplistic substitution of one set of medications for another, potentially leading to new forms of dependence or misuse.

### Norman Ohler's Argument for Distinction

- Psychedelics like LSD reduce energy in the control center of the brain less than addictive drugs
- Neanderthals did not use psychedelics, but humans did for millennia in rituals
- LSD is non-addictive, unlike cocaine which he terms a 'talking drug'

### Joanna Moncrieff's Concerns on Medicalization

- Worry that psychedelics replace antidepressants (SSRIs, benzos) without proven long-term benefit
- Psychedelic-assisted therapy is expensive, limiting regular use
- Cites clinical trial evidence not showing superior outcomes for PTSD or alcoholism

### Societal Implications

- Fear that the promotion of psychedelics as a solution leads to a 'mind control' scenario similar to the opioid crisis
- Current societal approach is potentially too fast and influenced by profit motives

![Screenshot at 0:01: Norman Ohler passionately gesturing while arguing about the fundamental differences between psychedelics and addictive substances during the panel discussion.](https://ss.rapidrecap.app/screens/S6Smi0GisB0/00-00-01.png)
![Screenshot at 0:08: The four panelists seated on stage with the title 'OUT OF OUR MINDS' displayed on the large blue screen behind them.](https://ss.rapidrecap.app/screens/S6Smi0GisB0/00-00-08.png)
![Screenshot at 0:33: Norman Ohler is identified as the author of 'Blitzed: Drugs in the Third Reich' while discussing historical drug use.](https://ss.rapidrecap.app/screens/S6Smi0GisB0/00-00-33.png)
![Screenshot at 1:11: A close-up of the two female panelists, one in green and one in a dark suit, listening intently during the debate.](https://ss.rapidrecap.app/screens/S6Smi0GisB0/00-01-11.png)
![Screenshot at 2:00: Norman Ohler explains his point about the Neanderthal brain structure being different from modern humans.](https://ss.rapidrecap.app/screens/S6Smi0GisB0/00-02-00.png)
![Screenshot at 3:03: Joanna Moncrieff details her reservations about the current enthusiasm for psychedelics in therapy, gesturing with her hands.](https://ss.rapidrecap.app/screens/S6Smi0GisB0/00-03-03.png)
![Screenshot at 4:50: The full panel view showing the dynamics as the discussion continues about societal acceptance and medical use.](https://ss.rapidrecap.app/screens/S6Smi0GisB0/00-04-50.png)
![Screenshot at 5:58: Norman Ohler making a gesture to illustrate the difference in addiction potential between psychedelics and other substances.](https://ss.rapidrecap.app/screens/S6Smi0GisB0/00-05-58.png)
![Screenshot at 7:21: Joanna Moncrieff elaborating on the cost and potential risks of normalizing psychedelic use for trauma processing.](https://ss.rapidrecap.app/screens/S6Smi0GisB0/00-07-21.png)
![Screenshot at 11:18: Norman Ohler and Joanna Moncrieff sharing a moment of connection and slight amusement after Moncrieff points out the problem with the current approach.](https://ss.rapidrecap.app/screens/S6Smi0GisB0/00-11-18.png)